Know the TT-103MH haemostatic agent for all kind of bleeding treatments discovered by Thrombotargets, the biotech corporation that works to improve the quality of life for millions of people.
We are developing the first antihemorrhagic drug useful for treating topically all kinds of bleeding. The most advanced drug candidate, TT-103MH, is a proprietary targeted antihemorrhagic human recombinant protein that induces a fast, efficient and stable blood coagulation.
Know the TT-103MH haemostatic agent for all kind of bleeding treatments discovered by Thrombotargets, the biotech corporation that works to improve the quality of life for millions of people.
The potent hemostatic effects of TT-103MH have also been observed in samples from patients with congenital platelet disorders, such as the Bernard-Soulier Syndrome and Glanzmann's Disease. Thrombotargets is developing the first antihemorrhagic drug useful for treating topically all kinds of bleeding. Know more about us.
|
